c-Met overexpression in inflammatory breast carcinomas: Automated quantification on tissue microarrays

British Journal of Cancer

Volumn 96, Issue 2, 2007, Pages 329-335

  Garcia, S ^a   Dales J P ^a   Jacquemier, J ^b   Charafe Jauffret, E ^b   Birnbaum, D ^b   Andrac Meyer, L ^a   Lavaut, M N ^a   Allasia, C ^c   Carpentier Meunier, S ^a   Bonnier, P ^d   Charpin Taranger, C ^a  

^a HÔPITAL NORD   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

c Met; Image analysis; Immunocytochemistry; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR RECEPTOR; UVOMORULIN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVICE; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; MASTITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AUTOMATION; BREAST NEOPLASMS; CADHERINS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS C-MET; TISSUE ARRAY ANALYSIS;

EID: 33846522264     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603569     Document Type: Article

References (38)

1. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P (2004) Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64: 8558-8565
2. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH (1997) Expression of the c-met/HGF receptor in human breast carcinoma: correlation with tumour progression. Int J Cancer 74: 301-309
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met,metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925
4. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN (1995) Combined modality treatment of stage III and inflammatory breast cancer. MD Anderson Cancer Center experience. Surg Oncol Clin N Am 4: 715-734
5. Camp RL, Chung GC, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327
6. Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86: 2259-2265
7. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 202: 265-273
8. Charpin C, Dalès JP, Garcia S, Carpentier S, Djemli A, Andrac L, Lavaut MN, Allasia C, Bonnier P (2004) Tumour neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res 10: 5815-5819
9. Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P, Lavaut MN, Allasia C (1997a) CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas. Correlation with patient follow-up. Am J Clin Pathol 107: 534-541
10. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut MN, Allasia C (1997b) Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 28: 289-296
11. Charpin C, Garcia S, Bouvier C, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN, Allasia C (1998a) Bcl-2 automated and quantitative immunocytochemical assays in breast carcinoma: correlation with 10 year follow-up. J Clin Oncol 16: 2025-2031
12. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN, Allasia C (1998b) Prognostic significance (ten year follow up) of Nm23/NDPK automated and quantitative immunocytochemical assays in breast carcinomas. J Pathol 184: 401-407
13. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Choux R, Lavaut MN, Allasia C (1998c) Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol 109: 431-438
14. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N, Piana L (1994) Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to mRNA expression and to immunohistochemical prognostic indicators. J Nat Canc Inst 20: 1539-1545
15. Christensen JG, Burrows J, Salgia R (2005) C-met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225: 1-26
16. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P (2003) A selective small molecule inhibitor of c-met kinase inhibits c-met-dependent phenotypes in vitro and exhibits cytoreductive antitumour activity in vivo. Cancer Res 63: 7345-7355
17. Dalès JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C (2005) Overexpression of hypoxia-inducible factor HIF-1a predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116: 734-739
18. Dalès JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C (2004) Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105 and CD31 immunocytochemical expression. Hum Pathol 35: 176-183
19. Gasparini G, Longo R, Fanelli M, Teicher BA (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions. J Clin Oncol 23: 1295-1311
20. Ghoussoub RA, Dillon DA, D'Aquila TG, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82: 1513-1520
21. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, Viens P, Mozziconacci MJ, Houlgatte R, Birnbaum D, Jacquemier J (2002) Distinct and complentary information provided by use of tissue and DNA microarrays in the study of breast tumour markers. Am J Pathol 161: 1223-1233
22. Jaiyesimi IA, Bulzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol 10: 1014-1024
23. Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662
24. Laird AD, Cherrington JM (2003) Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Invest Drugs 12: 51-64
25. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR (2005) Prognostic significance of co-expression of Ron and Met receptors in node-negative breast cancer patients. Clin Cancer Res 11: 2222-2228
26. Ma PC, Maulik G, Christensen J, Salgia R (2003) C-met: Structure, functions and potential for therapeutic inhibition. Cancer Meta Rev 22: 309-325
27. Matsumoto K, Nakamura T (2003) NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94: 321-327
28. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R (2002) Role of the hepatocyte growth factor receptor, c-met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13: 41-59
29. Morton PA, Joy WD, Bono CP, Arbuckle A, Evans ML, Huynh MS (2003) In vitro and in vivo activity of fully-human monoclonal antibody antagonists to c-met protein tyrosine kinase. Proc Am Assoc Cancer Res 43: 560
30. Nakipoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS (2000) C-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and unfavourable prognostic factors in invasive breast carcinoma. Histopathology 36: 313-325
31. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilosky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2006) Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 25: 2654-2666
32. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361
33. Schwall R, Adams WD, Zheng Z, Romero M, Mai E, Moffat B (2004) Inhibition of c-met activation by a one-armed antibody. Proc Am Assoc Cancer Res 44: 1424
34. Tavassoli F, Devilee P (2003) WHO Classification of Tumours. Tumours of Breast and Female Genital Organs. IARC Press, pp 47-49
35. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL (2003) Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that c-met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97: 1841-1848
36. Trusolino L, Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signaling for invasive growth. Nature 2: 289-300
37. Wang X, Le P, Liang C, Chan J, Kienlich D, Miller T (2003) Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumour cell growth and invasion. Mol Cancer Ther 2: 1085-1092
38. Zheng Z, Adams C, Moffat B, Schwall RA (2003) Chimeric Fab antibody serves as an antagonist to the HGF/SF receptor c-met. Proc Am Assoc Cancer Res 43: 5717